Triumeq-ENG (Dolutegravir+Abacavir+lamivudine Tablet) 50mg+600mg+300mg

Triumeq-ENG is a fixed-dose antiretroviral tablet combining dolutegravir, abacavir, and lamivudine for HIV-1 therapy. This once-daily regimen supports viral suppression and immune health in adults and adolescents. Prescription required. Store at room temperature.

Strength

50mg+600mg+300mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Glaxosmithkline

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Triumeq-ENG is used in the treatment of HIV-1 infection as part of a complete antiretroviral regimen. It combines three active ingredients to reduce viral load and maintain immune function. This medication is suitable for adults and adolescents weighing at least 40 kg. It is not a cure for HIV or AIDS, but helps manage the condition when taken regularly.

Side Effects

Triumeq-ENG works by interfering with the virus’s ability to replicate, helping to lower the amount of HIV in the body. Over time, this supports the immune system and may reduce the risk of HIV-related complications. Patients may notice improved energy levels and fewer opportunistic infections as treatment continues.

Precautions & Warnings

Triumeq-ENG should be taken exactly as prescribed by a healthcare provider. Do not start or stop this medication without medical advice. Keep all follow-up appointments to monitor treatment progress and side effects. Store the tablets in a cool, dry place away from moisture and heat. Keep out of reach of children.

Avoid Interactions

Triumeq-ENG may interact with other medications, including certain antacids, supplements, and herbal products. Avoid taking it with high-dose vitamin or mineral supplements unless directed. Some drugs, such as rifampin or certain anti-seizure medications, may reduce its effectiveness. Always inform your doctor about all medicines you are taking.

Frequently Asked Questions

Triumeq-ENG is used to treat HIV-1 infection in adults and adolescents weighing at least 40 kg.

Store Triumeq-ENG at room temperature, away from moisture and direct heat.

Consult your doctor before taking any new medications, as some may interact with Triumeq-ENG.

No, Triumeq-ENG helps manage HIV but is not a cure for the infection.

Take the missed dose as soon as you remember, but skip it if it is almost time for the next dose.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.